Concepedia

Tanay S. Samant

TS

8

Publications

448

Citations

8

H-Index

2017

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

National Cancer Centre Singapore

The University of Texas MD Anderson Cancer Center

Hospital General Universitario Gregorio Marañón

Tanay S. Samant is an author at Novartis (United States) specializing in medicine, pharmacology, and pharmacodynamic modeling.

ORCID

Top concepts

Publications per year

2017–2023

8

Publications

8

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 147 citations · Full text

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: <i>In Silico</i> and Clinical Evaluations

Tanay S. Samant, Shyeilla V. Dhuria, Yasong Lu et al. · Clinical Pharmacology & Therapeutics · 2017 · 77 citations · Full text

Food Effect Projections via Physiologically Based Pharmacokinetic Modeling: Predictive Case Studies

Christophe Tistaert, Tycho Heimbach, Binfeng Xia et al. · Journal of Pharmaceutical Sciences · 2018 · 76 citations

, , +11

Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults

Naveen Mangal, Issam S. Hamadeh, Meghan J. Arwood et al. · Clinical Pharmacology & Therapeutics · 2018 · 56 citations

Ribociclib Drug‐Drug Interactions: Clinical Evaluations and Physiologically‐Based Pharmacokinetic Modeling to Guide Drug Labeling

Tanay S. Samant, Felix Huth, Kenichi Umehara et al. · Clinical Pharmacology & Therapeutics · 2020 · 41 citations

Rows per page

1–5 of 8